Bio:

Christina Sveen finished her Bachelor Degree in 2020 as a Bioengineer before commencing her Master Degree in Bio Medicine at Oslo Metropolitan University (2020-2022). She performed her Master’s thesis under the supervision of Dr. Nikolai Engedal and Dr. Natalie Jayne Kurganovs, where she investigated the role of autophagy and autophagy-related genes in the development of melanoma. After graduating her Masters in June 2022, Sveen continued working as a Special Engineer in the “Autophagy in cancer” project group where she has contributed to numerous projects, including involvement in international collaborations.

Publications:

1. Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN, Flørenes VA, Prasmickaite L, Mælandsmo GM, Seip K (2022)
   AXL inhibition improves BRAF-targeted treatment in melanoma
   Sci Rep, 12 (1), 5076
   DOI 1038/s41598-022-09078-z, PubMed 35332208
2. Tamargo-Gómez I, Martínez-García GG, Suárez MF, Mayoral P, Bretones G, Astudillo A, Prieto-Lloret J, Sveen C, Fueyo A, Engedal N, López-Otín C, Mariño G (2023)
   Analysis of ATG4C function in vivo
   Autophagy, 1-22 (in press)
   DOI 1080/15548627.2023.2234799, PubMed 37459465